Indivior (OTCMKTS:INVVY – Get Free Report) and IM Cannabis (NASDAQ:IMCC – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.
Earnings & Valuation
This table compares Indivior and IM Cannabis”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Indivior | $791.00 million | 3.81 | $205.00 million | $1.05 | 20.81 |
| IM Cannabis | $39.17 million | 0.01 | -$8.10 million | ($60.66) | -0.03 |
Profitability
This table compares Indivior and IM Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Indivior | N/A | N/A | N/A |
| IM Cannabis | -39.62% | -585.96% | -58.32% |
Risk and Volatility
Indivior has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Indivior and IM Cannabis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Indivior | 0 | 0 | 1 | 0 | 3.00 |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
Indivior presently has a consensus target price of $50.00, suggesting a potential upside of 128.88%. Given Indivior’s stronger consensus rating and higher probable upside, research analysts clearly believe Indivior is more favorable than IM Cannabis.
Institutional & Insider Ownership
0.1% of Indivior shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 5.9% of IM Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Indivior beats IM Cannabis on 11 of the 14 factors compared between the two stocks.
About Indivior
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
